EGFR and hepatocellular carcinoma: Recently, one study has revealed that blocking EGFR by gefitinib and lenvatinib exhibited a relatively potent antitumour efficacy in HCC (27), whereas the activation status of EGFR and its downstream pathways (MEK/ERK and PI3K/AKT) after LR induction in HCC has not been fully understood.